Galderma Group AG

BATS-CHIXE:GALDZ Stock Report

Market Cap: CHF 21.3b

Galderma Group Future Growth

Future criteria checks 4/6

Galderma Group is forecast to grow earnings and revenue by 44.4% and 11.6% per annum respectively. EPS is expected to grow by 45.7% per annum. Return on equity is forecast to be 10.2% in 3 years.

Key information

44.4%

Earnings growth rate

45.7%

EPS growth rate

Pharmaceuticals earnings growth19.7%
Revenue growth rate11.6%
Future return on equity10.2%
Analyst coverage

Good

Last updated19 Nov 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BATS-CHIXE:GALDZ - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20265,7067688381,12910
12/31/20254,99049558184911
12/31/20244,44422629964311
6/30/20244,318-14216419N/A
3/31/20244,217-36115292N/A
12/31/20234,117-5713165N/A
12/31/20223,824-97-48111N/A
12/31/20213,445-8268196N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: GALDZ is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.1%).

Earnings vs Market: GALDZ is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: GALDZ is expected to become profitable in the next 3 years.

Revenue vs Market: GALDZ's revenue (11.6% per year) is forecast to grow faster than the UK market (3.5% per year).

High Growth Revenue: GALDZ's revenue (11.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GALDZ's Return on Equity is forecast to be low in 3 years time (10.2%).


Discover growth companies